Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV
Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV
"Dosing the first patient marks a pivotal step forward in Avirmax's mission to bring transformative gene therapies to patients suffering from severe retinal diseases.," said HAYWARD, Calif., Nov. 21, 2024 /PRNewswire/ -- Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company's first gene therapy drug for the treatment of Wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).
加利福尼亞州海沃德，2024年11月21日 / PRNewswire / - 阿維瑪克斯生物製藥公司（Avirmax Biopharma, Inc.）是在創新基因治療領域的領導者，今日宣佈該公司針對溼性年齡相關性黃斑變性（AMD）包括多形性脈絡膜視網膜病變（PCV）的首個基因治療藥物ABI-110的I / IIa期臨床試驗已成功爲首位患者投藥。
"We are thrilled to announce this significant milestone in the clinical investigation of ABI-110" said Shawn Liu, Ph.D., Chief Executive Officer of Avirmax Biopharma Inc. "ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV."
阿維瑪克斯生物製藥公司首席執行官劉岄博士表示:"我們很高興地宣佈此重要里程碑的到來，刊登在ABI-110的臨床研究中。"ABI-110有潛力革新溼性AMD和PCV的治療領域。
Avirmax doses first patient in Phase I/IIa trial of ABI-110, a pioneering gene therapy for Wet AMD and PCV
阿維瑪克斯首位患者接受ABI-110溼性AMD和PCV I / IIa試驗的劑量。
"Dosing the first patient marks a pivotal step forward in Avirmax's mission to bring transformative gene therapies to patients suffering from severe retinal diseases.," said Wendy Murahashi, M.D., Chief Medical Officer of Avirmax Biopharma Inc..
"爲首位患者注射劑量標誌着阿維瑪克斯向重視嚴重視網膜疾病的患者帶來變革性基因治療使命邁出重要一步。" 阿維瑪克斯生物製藥公司首席醫療官 Wendy Murahashi 萬博士表示。
Wet Age-related Macular Degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV) are serious retinal diseases that can lead to severe vision loss. Current treatments often require frequent injections and provide only temporary relief. ABI-110 has the potential to offer a more durable and effective solution by addressing the root causes of these conditions at the genetic level.
溼性年齡相關性黃斑變性（AMD）和多形性脈絡膜視網膜病變（PCV）是嚴重的視網膜疾病，可能導致嚴重視力損失。目前的治療通常需要頻繁注射，僅提供暫時緩解。 ABI-110有可能通過在基因水平上處理這些病症的根本原因，提供更持久有效的解決方案。
ABI-110, Avirmax Biopharma's proprietary gene therapy, utilizes an engineered capsid, AAV2.N54, to efficiently deliver therapeutic transgene to the macular retina. This approach aims to provide a long-lasting solution that goes beyond the limitations of current treatments. The Phase 1 clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ABI-110 in patients with Wet AMD and PCV.
Avirmax生物製藥公司的專有基因治療ABI-110利用經過改良的載體AAV2.N54，有效將治療性基因輸送到黃斑視網膜。這一方法旨在提供超越當前治療侷限的長期解決方案。I期臨床試驗旨在評估ABI-110在溼性AMD和PCV患者中的安全性、耐受性和初步療效。
About Avirmax Biopharma
關於阿維瑪克斯生物製藥
Avirmax Biopharma Inc., based in the San Francisco Bay Area, is a clinical stage biopharmaceutical company specializing in developing next-generation gene therapies for wet AMD, PCV, geographic atrophy (GA), dry AMD, glaucoma and diabetic retinopathy. Utilizing proprietary AAV vector technologies, Avirmax Biopharma aims to deliver safe, effective, and accessible gene therapies to improve patient outcomes and preserve vision. Visit us at for more information.
總部位於舊金山灣區的Avirmax生物製藥公司是一家臨床階段生物製藥公司，專門致力於開發下一代基因治療技術，用於治療濕性年齡相關性黃斑變性、脈絡膜新生血管、地理性萎縮症、乾性年齡相關性黃斑變性、青光眼和糖尿病性視網膜病變。Avirmax生物製藥公司利用專有的AAV載體技術，旨在提供安全、有效且可獲得的基因治療，改善患者預後並保持視力。欲了解更多信息，請訪問我們的網站。
Contact
聯繫方式
June Song, Associate Director for Operations
Email: [email protected]
Tel: +1-510-641-0201
運營副總監宋君
電子郵件: [email protected]
電話: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
地址
25503 Whitesell街
加利福尼亞州海沃德市94545
美國
SOURCE Avirmax
來源 Avirmax
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
